Wellell Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Wellell.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	21.2%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Some May Be Optimistic About Wellell's (TWSE:4106) Earnings

Mar 23

Should You Or Shouldn't You: A Dividend Analysis on Apex Medical Corp. (TPE:4106)

Mar 29

Reflecting on Apex Medical's (TPE:4106) Share Price Returns Over The Last Five Years

Mar 01

Returns On Capital At Apex Medical (TPE:4106) Paint An Interesting Picture

Feb 11

Weak Financial Prospects Seem To Be Dragging Down Apex Medical Corp. (TPE:4106) Stock

Jan 27

Is Apex Medical (TPE:4106) Using Too Much Debt?

Jan 12

Is Apex Medical Corp. (TPE:4106) A Good Fit For Your Dividend Portfolio?

Dec 28

Does Apex Medical's (TPE:4106) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 13

Apex Medical (TPE:4106) Share Prices Have Dropped 28% In The Last Five Years

Nov 27

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Wellell no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

TWSE:4106 - Estimaciones futuras de los analistas y datos financieros pasados (TWD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2023	2,647	152	424	456	N/A
9/30/2023	2,665	145	384	435	N/A
6/30/2023	2,792	181	223	274	N/A
3/31/2023	2,768	181	167	219	N/A
12/31/2022	2,664	161	34	82	N/A
9/30/2022	2,585	150	0	49	N/A
6/30/2022	2,492	121	-70	-17	N/A
3/31/2022	2,389	104	-68	-15	N/A
12/31/2021	2,374	102	-45	7	N/A
9/30/2021	2,310	109	-95	-91	N/A
6/30/2021	2,236	106	120	133	N/A
3/31/2021	2,168	126	153	197	N/A
12/31/2020	2,004	105	232	279	N/A
9/30/2020	1,967	110	293	369	N/A
6/30/2020	1,924	95	157	225	N/A
3/31/2020	1,938	58	136	170	N/A
12/31/2019	2,036	88	141	174	N/A
9/30/2019	2,088	104	-44	129	N/A
6/30/2019	2,100	118	-52	120	N/A
3/31/2019	2,122	123	18	192	N/A
12/31/2018	2,106	108	-54	119	N/A
9/30/2018	2,049	93	198	233	N/A
6/30/2018	2,122	90	205	235	N/A
3/31/2018	2,119	115	131	159	N/A
12/31/2017	2,089	118	154	178	N/A
9/30/2017	2,103	114	N/A	74	N/A
6/30/2017	1,967	117	N/A	107	N/A
3/31/2017	1,951	102	N/A	214	N/A
12/31/2016	1,990	123	N/A	218	N/A
9/30/2016	1,994	153	N/A	218	N/A
6/30/2016	1,983	143	N/A	249	N/A
3/31/2016	2,008	158	N/A	223	N/A
12/31/2015	2,016	169	N/A	277	N/A
9/30/2015	2,029	144	N/A	283	N/A
6/30/2015	2,165	175	N/A	219	N/A
3/31/2015	2,199	179	N/A	266	N/A
12/31/2014	2,263	178	N/A	248	N/A
9/30/2014	2,242	199	N/A	242	N/A
6/30/2014	2,181	164	N/A	199	N/A
3/31/2014	2,107	149	N/A	121	N/A
12/31/2013	2,017	133	N/A	219	N/A
9/30/2013	2,015	120	N/A	193	N/A
6/30/2013	1,941	148	N/A	401	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de 4106 es superior a la tasa de ahorro (0.8%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de 4106 crezcan más rápidamente que el mercado TW

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de 4106 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de 4106 crezcan más rápidamente que el mercado de TW.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de 4106 crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 4106 se prevé que sea elevada dentro de 3 años.

Wellell Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Apex (Kunshan)Medical Corp. to Announce Production Can Be Resume Gradually

Apex Medical Corp. Announces On Behalf of the Subsidiaries Apex (Kunshan) Medical Corp. and Wellell (Kunshan) Co., Ltd. Extend Temporary Suspension of Production

Wellell (Kunshan) Co., Ltd. Announces the Temporary Suspension of Production

Recent updates

Some May Be Optimistic About Wellell's (TWSE:4106) Earnings

Wellell Inc. Appoints Su Ya-Ling as Chief Operating Officer

Full year 2023 earnings released: EPS: NT$1.51 (vs NT$1.60 in FY 2022)

Wellell Inc., Annual General Meeting, Jun 24, 2024

Wellell Inc. Appoints Lee Pi Kai as Chief Strategy Officer

Wellell Inc. Announces Resignation of Tan, Jian-Qiang as Chief Operating Officer

Second quarter 2023 earnings released: EPS: NT$0.50 (vs NT$0.51 in 2Q 2022)

Upcoming dividend of NT$0.85 per share at 2.7% yield

New minor risk - Dividend sustainability

Investor sentiment improves as stock rises 16%

Wellell Inc. Appoints Shin-Ho,Chen as Corporate Governance Officer

Full year 2022 earnings released: EPS: NT$1.60 (vs NT$1.01 in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: NT$0.59 (vs NT$0.31 in 3Q 2021)

Insufficient new directors

Wellell Inc. Announces Change Member of Remuneration Committee

Second quarter 2022 earnings released: EPS: NT$0.51 (vs NT$0.34 in 2Q 2021)

Insufficient new directors

Apex Medical Corp. Approves Cash Dividend for the Year 2021

Apex Medical Corp. Announces Change of Alan Chang as Research and Development Officer, Effective May 31, 2022

Apex (Kunshan)Medical Corp. to Announce Production Can Be Resume Gradually

Apex Medical Corp. Announces On Behalf of the Subsidiaries Apex (Kunshan) Medical Corp. and Wellell (Kunshan) Co., Ltd. Extend Temporary Suspension of Production

Wellell (Kunshan) Co., Ltd. Announces the Temporary Suspension of Production

Full year 2021 earnings released: EPS: NT$1.01 (vs NT$1.04 in FY 2020)

Wellell Inc., Annual General Meeting, Jun 20, 2022

Third quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.28 in 3Q 2020)

High number of new directors

High number of new directors

High number of new directors

Upcoming dividend of NT$0.55 per share

Second quarter 2021 earnings released: EPS NT$0.34 (vs NT$0.55 in 2Q 2020)

High number of new directors

High number of new directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS NT$0.29 (vs NT$0.074 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS NT$1.04 (vs NT$0.87 in FY 2019)

Should You Or Shouldn't You: A Dividend Analysis on Apex Medical Corp. (TPE:4106)

Reflecting on Apex Medical's (TPE:4106) Share Price Returns Over The Last Five Years

Apex Medical Corp. Announces Executive Changes, Effective March 01, 2021

Returns On Capital At Apex Medical (TPE:4106) Paint An Interesting Picture

Apex Medical Corp. Appoints Alan Chang as Director of R&D

New 90-day low: NT$25.65

Weak Financial Prospects Seem To Be Dragging Down Apex Medical Corp. (TPE:4106) Stock

Is Apex Medical (TPE:4106) Using Too Much Debt?

New 90-day low: NT$28.00

Is Apex Medical Corp. (TPE:4106) A Good Fit For Your Dividend Portfolio?

Does Apex Medical's (TPE:4106) Statutory Profit Adequately Reflect Its Underlying Profit?

New 90-day low: NT$28.90

Apex Medical (TPE:4106) Share Prices Have Dropped 28% In The Last Five Years

Third quarter 2020 earnings released: EPS NT$0.28

New 90-day low: NT$31.05

First half earnings released

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento